艾克司单抗治疗银屑病、银屑病关节炎和中轴型脊柱关节炎的长期安全性:21项临床试验整合分析
该整合分析基于21项临床试验,评估艾克司单抗在成人银屑病、银屑病关节炎和中轴型脊柱关节炎患者中的长期安全性与耐受性。
要点
- 最常见TEAE为鼻咽炎、上呼吸道感染和注射部位反应。
- 导致停药AE、严重AE和死亡的调整发生率均较低。
- 特殊关注TEAE以感染最常见,恶性肿瘤、IBD和MACE罕见。
核心结论
- 艾克司单抗长期安全性与此前已发表报告一致,未显示任何新安全信号。
研究设计与样本
- 整合21项临床试验的安全性数据,按适应症分析接受至少一剂艾克司单抗的成人患者。
- 报告至多5年暴露期间的不良事件和治疗中出现的不良事件每100患者年调整发生率。
主要发现
- 导致停药的AE发生率≤5.1/100患者年,严重AE发生率≤6.0/100患者年,死亡发生率≤0.3/100患者年。
- 特殊关注TEAE中最常报告为感染,发生率≤35.8/100患者年。
- 恶性肿瘤(IR≤0.8)、IBD包括溃疡性结肠炎和克罗恩病(IR≤0.8)及主要不良心血管事件(IR≤0.5)罕见报告。
- TEAE最常在艾克司单抗暴露前2年报告,感染、注射部位反应和抑郁的IR随年份下降,严重感染、MACE、恶性肿瘤和IBD的IR在整个治疗期间保持恒定。
临床怎么用
- 长期使用艾克司单抗时,应关注感染、注射部位反应等常见不良事件,前2年尤其需监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA. METHODS: Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab. Adverse events (AEs) and treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100 patient-years (PY) up to 5 years' exposure are reported. RESULTS: A total of 8228 patients with an ixekizumab exposure of 20 895.9 PY were included in this analysis. The most common TEAEs were nasopharyngitis, upper respiratory tract infection and injection-site reactions. Across populations, IRs were low for AEs leading to discontinuation (IRs ≤5.1 per 100 PY), serious AEs (IRs ≤6.0 per 100 PY) and death (IRs ≤0.3 per 100 PY). The most reported TEAEs of special interest were infections (IRs ≤35.8 per 100 PY). Patients rarely reported malignancies (IR ≤0.8), IBD including ulcerative colitis and Crohn's disease (IR ≤0.8) and major adverse cardiovascular events (IR ≤0.5). TEAEs were most commonly reported the first 2 years of exposure with ixekizumab and IR decreased over the years (infections, injection-site reactions and depression) or remained constant over the entire treatment period (serious infections, major adverse cardiovascular events, malignancies and IBD). CONCLUSION: This long-term analysis on the safety of ixekizumab was consistent with previously published reports and did not show any new safety signals. The safety profile and tolerability reported in this integrated analysis remained consistent with the known safety profile for ixekizumab.
引用
- Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020. PMID: 32449924. doi:10.1093/rheumatology/keaa189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。